Compounds > u 99194a
Page last updated: 2024-09-25

u 99194a

Description

(5,6-dimethoxyindan-2-yl)dipropylamine: has 20-fold preference for D3 versus D2 dopamine receptors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119195
CHEMBL ID543760
MeSH IDM0228883

Synonyms (18)

Synonym
u 99194a
(5,6-dimethoxyindan-2-yl)dipropylamine
1h-inden-2-amine, 2,3-dihydro-5,6-dimethoxy-n,n-dipropyl-, hydrochloride
u-99194a
5,6-dimethoxy-n,n-dipropyl-2,3-dihydro-1h-inden-2-amine hydrochloride
pnu 99194a
pnu-99194a
153570-58-2
CHEMBL543760
83598-46-3
unii-e5a8b0v7p3
e5a8b0v7p3 ,
1h-inden-2-amine, 2,3-dihydro-5,6-dimethoxy-n,n-dipropyl-, hydrochloride (1:1)
u99194a
5,6-dimethoxy-n,n-dipropyl-2,3-dihydro-1h-inden-2-amine--hydrogen chloride (1/1)
DTXSID50934780
Q27276891
5,6-dimethoxy-n,n-dipropyl-2,3-dihydro-1h-inden-2-amine;hydrochloride

Bioassays (3)

Assay IDTitleYearJournalArticle
AID48365Inhibition of the positive chronotropic effect of stimulation of the cardioaccelerator nerve in the anesthetized cat.1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Conformationally restricted congeners of dopamine derived from 2-aminoindan.
AID62450Inhibitory binding activity against dopamine receptor using [3H]spiperone as the radioligand in striatal tissue of calf brain.1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Conformationally restricted congeners of dopamine derived from 2-aminoindan.
AID62448Inhibitory binding activity against dopamine receptor using [3H]ADTN as the radioligand in striatal tissue of calf brain.1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Conformationally restricted congeners of dopamine derived from 2-aminoindan.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (59)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.69)18.7374
1990's19 (32.20)18.2507
2000's27 (45.76)29.6817
2010's12 (20.34)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other62 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
apomorphine[no description available]medium30aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
lergotrile[no description available]medium10organic heterotetracyclic compound;
organonitrogen heterocyclic compound
7-hydroxy-2-n,n-dipropylaminotetralin[no description available]medium210tetralins
haloperidol[no description available]medium90aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
piperidines[no description available]medium70
rs 67333[no description available]medium10aromatic ketone
piboserod[no description available]medium10
ibotenic acid[no description available]medium10non-proteinogenic alpha-amino acidneurotoxin
l 741626[no description available]medium20piperidines
gr 103691[no description available]medium50aromatic ketone
sb 277011[no description available]medium40
dextroamphetamine[no description available]medium601-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
sch 23390[no description available]medium10benzazepine
nicardipine[no description available]medium10benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
3,4,4a,10b-tetrahydro-4-propyl-2h,5h-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol[no description available]medium140
7-hydroxy-2-(n-n-propyl-n-(3-iodo-2'-propenyl)-amino)tetralin[no description available]medium10organoiodine compound;
phenols;
tertiary amino compound;
tetralins		dopamine agonist
lactacystin[no description available]medium10lactam;
S-substituted L-cysteine
acetylcysteine[no description available]medium10acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
thiazoles[no description available]medium101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
gamma-aminobutyric acid[no description available]medium10amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
sulpiride[no description available]medium60benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
pramipexole[no description available]medium10benzothiazoles;
diamine		antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger
quinpirole[no description available]medium60pyrazoloquinolinedopamine agonist
raclopride[no description available]medium60salicylamides
3-hydroxybenzylhydrazine[no description available]medium10phenols
hydrazine[no description available]medium10azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
3,4-dihydroxyphenylacetic acid[no description available]medium10catechols;
dihydroxyphenylacetic acid		human metabolite
cocaine[no description available]medium60benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
nafadotride[no description available]medium50aromatic ether;
naphthalenecarboxamide;
nitrile;
pyrrolidines;
tertiary amino compound		dopaminergic antagonist
bp 897[no description available]medium10naphthalenecarboxamide
amphetamine[no description available]medium50primary amine
pyrroles[no description available]medium20pyrrole;
secondary amine
l 750667[no description available]medium10piperazines
risperidone[no description available]medium101,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride[no description available]medium10
domperidone[no description available]medium10benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
chlorpromazine[no description available]medium10organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
clozapine[no description available]medium30benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
remoxipride[no description available]medium30dimethoxybenzene
butaclamol[no description available]medium10
l 741742[no description available]medium10primary amine
isoxazoles[no description available]medium10isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
gbr 12935[no description available]medium10ether;
N-alkylpiperazine;
tertiary amino compound		dopamine uptake inhibitor
eticlopride[no description available]medium10salicylamides
methamphetamine[no description available]medium10amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
5-(dipropylamino)-5,6-dihydro-4h-imidazo-(5,1ij)quinolin-2(1h)-one[no description available]medium10
spiperone[no description available]medium10aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
reserpine[no description available]medium10alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
alpha-methyltyrosine methyl ester[no description available]medium10
preclamol[no description available]medium20
sk&f-38393[no description available]medium10benzazepine;
catechols;
secondary amino compound
8-hydroxy-2-(di-n-propylamino)tetralin[no description available]medium30phenols;
tertiary amino compound;
tetralins		serotonergic antagonist
2-naphthylamine[no description available]medium10naphthylaminecarcinogenic agent
s 14297[no description available]medium10
tetradecanoylphorbol acetate[no description available]medium10acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
arachidonic acid[no description available]medium10icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
quinelorane[no description available]medium10quinazolines
morphine[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
pirenzepine[no description available]medium10pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist
5-hydroxy-1-methyl-2--(di-n-propylamino)tetralin methyl ether[no description available]medium10
guanosine triphosphate[no description available]medium10guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
1,3-ditolylguanidine[no description available]medium10toluenes
iodosulpride[no description available]medium10
gr 218231[no description available]medium10
tetrodotoxin[no description available]medium10azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
l 745870[no description available]medium10piperazines
diazepam[no description available]medium101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
oxidopamine[no description available]medium10benzenetriol;
catecholamine;
primary amino compound		drug metabolite;
human metabolite;
neurotoxin
scopolamine hydrobromide[no description available]medium10
ConditionIndicatedRelationship StrengthStudiesTrials
ADDH0low10
Aggression0low10
Aging0low10
Anochlesia0low20
Anxiety0low20
Atherosclerotic Parkinsonism0low10
Attention Deficit Disorder0low10
Attention Deficit Disorder with Hyperactivity0low10
Attention Deficit Disorders with Hyperactivity0low10
Attention Deficit Hyperactivity Disorder0low10
Attention Deficit Hyperactivity Disorders0low10
Attention Deficit-Hyperactivity Disorder0low10
Blood Pressure, High0low10
Brain Dysfunction, Minimal0low10
Catalepsy0low20
Cerea Flexibilitas0low20
Chemical Dependence0low20
Chorea0low10
Chorea Disorders0low10
Chorea Syndromes0low10
Chorea, Benign Hereditary0low10
Chorea, Chronic Progressive0low10
Chorea, Rheumatic0low10
Chorea, Senile0low10
Chorea, Sydenham0low10
Choreatic Disorders0low10
Choreatic Syndromes0low10
Choreic Movement0low10
Choreiform Movement0low10
Dementia Praecox0low10
Disease Models, Animal0low50
Drug Abuse0low20
Drug Addiction0low20
Drug Dependence0low20
Drug Habituation0low20
Drug Use Disorders0low20
Dyskinesias, Paroxysmal0low10
Dystonia0low10
Dystonia, Diurnal0low10
Dystonia, Limb0low10
Dystonia, Paroxysmal0low10
Emesis0low10
Flexibility, Waxy0low20
Glaucoma0low10
Hereditary Chorea0low10
Hereditary Progressive Chorea Without Dementia0low10
Hyperkinetic Syndrome0low10
Hypertension0low10
Intraocular Pressure0low20
Minimal Brain Dysfunction0low10
MPTP Neurotoxicity Syndrome0low10
MPTP Poisoning0low10
MPTP-Induced Degeneration of the Striatum0low10
MPTP-Induced Parkinsonism0low10
Muscle Dystonia0low10
Neurotoxicity Syndrome, MPTP0low10
Organic Mental Disorders, Substance-Induced0low20
Parkinson Disease, Secondary0low10
Parkinson Disease, Secondary Vascular0low10
Parkinson Disease, Symptomatic0low10
Parkinsonism, Secondary0low10
Parkinsonism, Symptomatic0low10
Paroxysmal Dyskinesias0low10
Poisoning, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine0low10
Prescription Drug Abuse0low20
Rheumatic Chorea0low10
Schizophrenia0low10
Schizophrenic Disorders0low10
Secondary Parkinsonism0low10
Secondary Vascular Parkinson Disease0low10
Senile Chorea0low10
St. Vitus's Dance0low10
Substance Abuse0low20
Substance Addiction0low20
Substance Dependence0low20
Substance Use0low20
Substance Use Disorders0low20
Substance-Related Disorders0low20
Sydenham Chorea0low10
Sydenham's Chorea0low10
Symptomatic Parkinson Disease0low10
Vomiting0low10

Research Highlights

Long-term Use (2)

ArticleYear
Methamphetamine-induced locomotor activity and behavioral sensitization: are dopamine d3 receptors involved?
Cellular and molecular biology (Noisy-le-Grand, France), May-15, Volume: 53, Issue: 4		2007
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (5)

ArticleYear
Role of cerebellar dopamine D(3) receptors in modulating exploratory locomotion and cataleptogenicity in rats.
Progress in neuro-psychopharmacology & biological psychiatry, Apr-03, Volume: 50		2014
In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder.
The Journal of pharmacology and experimental therapeutics, Volume: 344, Issue: 2		2013
Quinpirole-induced 50 kHz ultrasonic vocalization in the rat: role of D2 and D3 dopamine receptors.
Behavioural brain research, Jan-15, Volume: 226, Issue: 2		2012
Antagonism of the discriminative stimulus effects of (+)-7-OH-DPAT by remoxipride but not PNU-99194A.
Pharmacology, biochemistry, and behavior, Volume: 68, Issue: 3		2001
The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew).
Journal of neural transmission (Vienna, Austria : 1996), Volume: 106, Issue: 11-12		1999
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]